Development and characterisation of Affimer binders to 4 leading therapeutic antibodies

Antibodies represent established affinity reagents for use in the regulatory bioanalysis of biologics. Yet, these reagents are associated with limitations that often present challenges with supply, stability and batch-to-batch variation on assay performance.

Our new application note outlines our established development and characterisation process for Affimer binders to four of the leading therapeutic antibodies- Trastuzumab, Rituximab, Adalimumab and Ipilimumab- for use as PK assay reagents.

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Avacta Group shortlisted for Biotech Company of the Year

The finalists in the 2020 Cambridge Independent Science and Technology Awards can now be revealed. Following hundreds of entries, a shortlist across 14 categories has been drawn up. Biotech Company of the Year, sponsored by Appleyard Lees Avacta

Avacta Group Plc

Avacta and COVID-19

Avacta is supporting global efforts in combating the COVID-19 pandemic by using its Affimer®  platform to develop diagnostic reagents for COVID-19 ANTIGEN testing. Avacta has generated a large number of Affimer binders to the SARS-COV-2 virus

Avacta Group Plc

Elisa test launch

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech

Avacta Group Plc

Cytiva strengthens support to diagnostics industry

Cytiva launches new services for diagnostic developers and will establish new labs to meet the future needs of the industry. Cytiva Diagnostic Services will help developers bring point-of-care diagnostic tests to market quicker through infrastructure, expertise and consultation for

Avacta Group Plc

Avacta set for “momentous milestones”

The Wetherby-based firm hopes to get the test, which works like a pregnancy test but uses saliva, validated before the end of 2020, which could be a game changer for the UK’s testing capability. Analyst Mark

Avacta Group Plc

‘Transformational’ year ahead for Avacta Group

Avacta Group’s CEO predicts a “transformational year” ahead with “momentous milestones” for the company as it progresses its Covid-19 test and other products. The Whittlesford-based drug development company unveiled interim results for the six months to

Avacta Group Plc

Avacta Group launch of SARS-CoV-2 BAMS research test

Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced that the BAMS assay to detect the SARS-CoV-2 virus has been launched as a research

Avacta Group Plc

Avacta hails “period of significant advancement”

Listed biotechnology business Avacta Group has hailed a “period of significant advancement” in its interim results, with “several momentous milestones” now on the horizon. The company, which as sites in Wetherby and Cambridge, reported revenue of

Avacta Group Plc

Avacta Group appoints Stifel Nicolaus Europe as joint broker

Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced the appointment of Stifel Nicolaus Europe Limited as joint broker with immediate effect.

Avacta Group Plc

Avacta Group “a period of significant advancement”

Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced its unaudited interim results for the six-month period ended 30 June 2020. Operating highlights Avacta

Avacta Group Plc

More progress unveiled in collaboration against Covid-19

York-based life sciences business Integumen has announced progress on its COVID-19 wastewater detection system, Microtox PD, in collaboration with Modern Water plc, Avacta Group and Aptamer Group Limited.  Integumen is working with a consortium of companies